Ozdamar Osman Ilkay, Ozbilen Acar Gul
Istanbul Medeniyet University Goztepe Training and Research Hospital, Department of Otorhinolaryngology Head and Neck Surgery, Istanbul, Turkey.
Medeni Med J. 2020;35(1):1-7. doi: 10.5222/MMJ.2020.78614. Epub 2020 Feb 28.
The goal of the study was to verify the efficacy and safety of topical medical treatment in idiopathic recurrent pediatric epistaxis patients by intranasal usage of both an antimicrobial and a moisturizing agent as a first-step management modality.
Sixty-seven out of 326 pediatric patients with idiopathic recurrent epistaxis selected on a chart review of follow-up were enrolled in the study. The study was designed as an analysis of two groups: one group included 35 individuals (52.2% of the total cohort) having a hyperemic nasal mucosa and the second group included 32 individuals (47.8% of the total cohort) having a hypervascular nasal mucosa on physical examination before treatment.
The study was performed with a total of 67 children (age range 3-17 years) including 36 males (53.7% of total cohort) and 31 females (46.3% of total cohort). The mean age was 9.78±4.09 years. There was not any statistically significant difference between the groups in terms of age, duration of follow-up and recurrence time of epistaxis (p>0.05). Recurrence of epistaxis was seen in 22.9% (8/35) of hyperemic nasal mucosa group and in 34.4% (11/32) of hypervascular nasal mucosa group (p>0.05).
We advise the use of both an intranasal antimicrobial ointment and a mucosal moisturizing gel as an effective, noninvasive and easily applicable medical treatment option for pediatric patients with idiopathic recurrent epistaxis before more invasive methods of epistaxis control.
本研究的目的是通过鼻内使用抗菌剂和保湿剂作为第一步管理方式,验证局部药物治疗在小儿特发性复发性鼻出血患者中的疗效和安全性。
在对随访病历进行回顾性分析后,从326例小儿特发性复发性鼻出血患者中选取67例纳入研究。本研究设计为两组分析:一组包括35例(占总队列的52.2%)鼻黏膜充血的个体,另一组包括32例(占总队列的47.8%)治疗前体格检查发现鼻黏膜血管增生的个体。
本研究共纳入67例儿童(年龄范围3 - 17岁),其中男性36例(占总队列的53.7%),女性31例(占总队列的46.3%)。平均年龄为9.78±4.09岁。两组在年龄、随访时间和鼻出血复发时间方面均无统计学显著差异(p>0.05)。鼻黏膜充血组鼻出血复发率为22.9%(8/35),鼻黏膜血管增生组为34.4%(11/32)(p>0.05)。
我们建议在采用更具侵入性的鼻出血控制方法之前,将鼻内抗菌软膏和黏膜保湿凝胶作为小儿特发性复发性鼻出血患者一种有效、无创且易于应用的药物治疗选择。